Why Under Armour (UAA) Is Up 8.8% After Margin-Focused FY27 Guidance And Restructuring Update
Under Armour, Inc. Class A UAA | 0.00 |
- Under Armour recently reported its fourth-quarter fiscal 2026 results, posting an adjusted loss of US$0.03 per share that matched expectations, with strong international growth and direct-to-consumer gains offsetting weaker North America and wholesale performance, alongside updates that its restructuring program should be largely complete by the end of 2026 at slightly higher total costs.
- The company also issued fiscal 2027 guidance calling for modest revenue declines but margin expansion and US$140 million to US$160 million in adjusted operating income, underpinned in part by tariff-related benefits even as it continues to invest amid ongoing cost pressures.
- Now, we’ll consider how this mix of margin-focused guidance and progress on restructuring may reshape Under Armour’s existing investment narrative.
The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
Under Armour Investment Narrative Recap
To own Under Armour today, you need to believe the brand can convert its ongoing restructuring and margin work into a sustainable return to profitability, even with modest revenue pressure. The latest results and fiscal 2027 outlook largely reinforce that near term, the key catalyst is margin execution, while the biggest risk remains operational and demand weakness, particularly in North America and wholesale. This news does not materially change that balance, but it sharpens the focus on cost discipline.
The most relevant update here is management’s fiscal 2027 guidance for low single digit revenue declines alongside expected margin expansion and US$140 million to US$160 million in adjusted operating income. That outlook ties directly to the catalyst of margin repair, including tariff related benefits, while set against risks around still soft demand and ongoing cost pressures. How effectively Under Armour progresses its restructuring by late 2026 will likely influence how durable any margin improvement proves to be.
Yet beneath the margin story, investors also need to be aware of potential pressure from limited digital relevance and weaker traction with younger consumers...
Under Armour’s narrative projects $5.5 billion revenue and $224.5 million earnings by 2029. This requires 3.2% yearly revenue growth and a $744.2 million earnings increase from -$519.7 million today.
Uncover how Under Armour's forecasts yield a $7.73 fair value, a 28% upside to its current price.
Exploring Other Perspectives
The lowest ranked analysts paint a much tougher picture, assuming roughly flat revenues around US$5.1 billion and earnings of only about US$131 million by 2028. Compared with the margin focused guidance and concerns about digital weakness, their forecasts highlight how differently you might weigh the same risks, and how this new earnings update could eventually shift both the cautious and more optimistic viewpoints.
Explore 6 other fair value estimates on Under Armour - why the stock might be worth less than half the current price!
Form Your Own Verdict
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Under Armour research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Under Armour research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Under Armour's overall financial health at a glance.
Seeking Other Investments?
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
- Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
